Logo image of VRNA

VERONA PHARMA PLC - ADR (VRNA) Stock Price, Quote, News and Overview

NASDAQ:VRNA - Nasdaq - US9250501064 - ADR - Currency: USD

72.73  +0.47 (+0.65%)

After market: 72.73 0 (0%)

VRNA Quote, Performance and Key Statistics

VERONA PHARMA PLC - ADR

NASDAQ:VRNA (5/2/2025, 8:28:04 PM)

After market: 72.73 0 (0%)

72.73

+0.47 (+0.65%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High74.18
52 Week Low11.39
Market Cap6.18B
Shares85.02M
Float45.30M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE249.31
Earnings (Next)08-06 2025-08-06
IPO03-30 2005-03-30


VRNA short term performance overview.The bars show the price performance of VRNA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

VRNA long term performance overview.The bars show the price performance of VRNA in the last 1, 2 and 3 years. 1 year 2 years 3 years 500 1K 1.5K

The current stock price of VRNA is 72.73 USD. In the past month the price increased by 25.2%. In the past year, price increased by 363.54%.

VERONA PHARMA PLC - ADR / VRNA Daily stock chart

VRNA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 59.86 780.78B
JNJ JOHNSON & JOHNSON 15.53 375.64B
NVO NOVO-NORDISK A/S-SPONS ADR 20.07 307.32B
NVS NOVARTIS AG-SPONSORED ADR 13.75 225.73B
AZN ASTRAZENECA PLC-SPONS ADR 19.47 224.59B
MRK MERCK & CO. INC. 10.68 209.31B
PFE PFIZER INC 7.54 137.25B
SNY SANOFI-ADR 14.4 135.72B
BMY BRISTOL-MYERS SQUIBB CO 6.89 102.91B
GSK GSK PLC-SPON ADR 7.16 79.05B
ZTS ZOETIS INC 26.59 70.23B
HLN HALEON PLC-ADR 22.29 48.25B

About VRNA

Company Profile

VRNA logo image Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. The company is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The firm's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The firm's wholly owned subsidiary is Verona Pharma, Inc.

Company Info

VERONA PHARMA PLC - ADR

Riverside, 3 More London Place

London SE1 2RE GB

CEO: David Zaccardelli

Employees: 209

VRNA Company Website

VRNA Investor Relations

Phone: 442032834200

VERONA PHARMA PLC - ADR / VRNA FAQ

What is the stock price of VERONA PHARMA PLC - ADR today?

The current stock price of VRNA is 72.73 USD. The price increased by 0.65% in the last trading session.


What is the ticker symbol for VERONA PHARMA PLC - ADR stock?

The exchange symbol of VERONA PHARMA PLC - ADR is VRNA and it is listed on the Nasdaq exchange.


On which exchange is VRNA stock listed?

VRNA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VERONA PHARMA PLC - ADR stock?

17 analysts have analysed VRNA and the average price target is 81.94 USD. This implies a price increase of 12.66% is expected in the next year compared to the current price of 72.73. Check the VERONA PHARMA PLC - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VERONA PHARMA PLC - ADR worth?

VERONA PHARMA PLC - ADR (VRNA) has a market capitalization of 6.18B USD. This makes VRNA a Mid Cap stock.


How many employees does VERONA PHARMA PLC - ADR have?

VERONA PHARMA PLC - ADR (VRNA) currently has 209 employees.


What are the support and resistance levels for VERONA PHARMA PLC - ADR (VRNA) stock?

VERONA PHARMA PLC - ADR (VRNA) has a support level at 57.62. Check the full technical report for a detailed analysis of VRNA support and resistance levels.


Is VERONA PHARMA PLC - ADR (VRNA) expected to grow?

The Revenue of VERONA PHARMA PLC - ADR (VRNA) is expected to grow by 730.42% in the next year. Check the estimates tab for more information on the VRNA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VERONA PHARMA PLC - ADR (VRNA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VERONA PHARMA PLC - ADR (VRNA) stock pay dividends?

VRNA does not pay a dividend.


When does VERONA PHARMA PLC - ADR (VRNA) report earnings?

VERONA PHARMA PLC - ADR (VRNA) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of VERONA PHARMA PLC - ADR (VRNA)?

VERONA PHARMA PLC - ADR (VRNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.16).


What is the Short Interest ratio of VERONA PHARMA PLC - ADR (VRNA) stock?

The outstanding short interest for VERONA PHARMA PLC - ADR (VRNA) is 17.2% of its float. Check the ownership tab for more information on the VRNA short interest.


VRNA Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to VRNA. When comparing the yearly performance of all stocks, VRNA is one of the better performing stocks in the market, outperforming 99.42% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VRNA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to VRNA. VRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VRNA Financial Highlights

Over the last trailing twelve months VRNA reported a non-GAAP Earnings per Share(EPS) of -2.16. The EPS decreased by -217.65% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -36.57%
ROE -84.78%
Debt/Equity 0.59
Chartmill High Growth Momentum
EPS Q2Q%-122.22%
Sales Q2Q%N/A
EPS 1Y (TTM)-217.65%
Revenue 1Y (TTM)N/A

VRNA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to VRNA. The Buy consensus is the average rating of analysts ratings from 17 analysts.

For the next year, analysts expect an EPS growth of 113.51% and a revenue growth 730.42% for VRNA


Ownership
Inst Owners71.35%
Ins Owners5.81%
Short Float %17.2%
Short Ratio5.59
Analysts
Analysts84.71
Price Target81.94 (12.66%)
EPS Next Y113.51%
Revenue Next Year730.42%